Wedbush Raises Price Target on Zumiez, Inc. (ZUMZ) to $18; Reiterates Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Stifel Raises Price Target on Zumiez, Inc. (ZUMZ) to $18 Following Comp Sales Report
October 6, 2016 10:04 AM EDTStifel reiterated a Hold rating on Zumiez, Inc. (NASDAQ: ZUMZ), and raised the price target to $18.00 (from $17.00), following the company's September comparable sales report. Comp sales increased 6.3%, better than the consensus estimate of 2%. Management provided an improved outlook for 3Q, given the... More
William Blair Upgrades Zumiez, Inc. (ZUMZ) to Outperform
October 6, 2016 7:30 AM EDTWilliam Blair upgraded Zumiez, Inc. (NASDAQ: ZUMZ) from Market Perform to Outperform.
For an analyst ratings summary and ratings history on Zumiez, Inc. click here. For more ratings news on Zumiez, Inc. click here.
Shares of Zumiez, Inc. closed at $18.27 yesterday.
... MoreB. Riley Upgrades Zumiez, Inc. (ZUMZ) to Buy
October 6, 2016 7:28 AM EDTB. Riley upgraded Zumiez, Inc. (NASDAQ: ZUMZ) from Neutral to Buy with a price target of $25.00.
For an analyst ratings summary and ratings history on Zumiez, Inc. click here. For more ratings news on Zumiez, Inc. click here.
Shares of Zumiez, Inc. closed at $18.27 yesterday.
... MoreAfter-Hours Stock Movers 10/05: (SCYX) (ZUMZ) (JD) Higher; (ALNY) (IDRA) (MDCO) Lower (more...)
October 5, 2016 6:10 PM EDTToday's After-Hours Movers
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) 42.3% LOWER; announced that upon the recommendation of the ENDEAVOUR Phase 3 study Data Monitoring Committee (DMC) to suspend dosing, the Company has decided to discontinue development of revusiran, an investigational RNA interference (RNAi) therapeutic that was being developed for the treatment of hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM). This decision was made yesterday evening and has been communicated to investigators, study sites, and regulatory authorities.
Zumiez, Inc. (ZUMZ) Comps Increased 6.3% in Sept.; Raises Q3 Guidance
October 5, 2016 4:02 PM EDTZumiez Inc. (NASDAQ: ZUMZ) announced that total net sales for the five-week period ended October 1, 2016 increased 11.5% to $75.0 million, compared to $67.3 million for the five-week period ended October 3, 2015. The Company's comparable sales increased 6.3% for the five-week period compared to a comparable sales decrease of... More
